Yonguc T, Sefik E, Inci I, et al. - In Parkinson disease (PD) patients with overactive bladder (OAB) symptoms, researchers conducted this randomized, double-blind, placebo-controlled study to test short-term effectiveness and safety of fesoterodine fumarate. Sixty-three patients were randomized to receive fesoterodine 4 mg or placebo for 4 weeks from May 2016 to May 2018. Study participants were received fesoterodine fumarate 4 mg daily for another 4 weeks at the open-label extension phase at the end of 4 weeks of randomization phase. In the double-blind phase, the number of micturition episodes per 24 h period significantly improved with the use of fesoterodine fumarate. In the fesoterodine group, the mean number of nocturia and urgency episodes also reduced. According to findings, OAB symptoms in older adults with PD under fesoterodine fumarate treatment have been significantly improved, and this benefit has continued in the short-term open-label portion. Participants' cognitive functions were not impaired by the treatment of fesoterodine 4 mg compared with placebo.